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Improving survival remains the primary objective of therapy for
most treatable cancers. However, as rates of long-term remission
and cure following therapy for certain malignancies improve,
achieving this with a minimum of late side-effects is becoming
more important. There is a great deal of evidence to suggest that
various aspects of quality of life are reduced in survivors of cancer
(Fobair et al, 1986; Berglund et al, 1991; Bjordal et al, 1994;
Hjermstad and Kaasa, 1995; Greenberg et al, 1997). Therefore,
assessment of quality of life after therapy is a vital part of deter-
mining the overall efficacy of different treatment regimens.
Furthermore, it is important to delineate a cause for these side-
effects as this may facilitate the development of strategies for their
prevention or treatment.
Alterations in mood are very common in long-term survivors of
malignancy. An increased incidence of anxiety and depression has
been described after treatment of various cancers (Fobair et al,
1986; Devlen et al, 1987; Ahles et al, 1996; Aass et al, 1997) using
various different standardized questionnaires. In addition, sexual
dysfunction is a relatively frequent problem in patients following
treatment for malignancy (Fobair et al, 1986; Bloom et al, 1993;
Hjermstad and Kaasa, 1995), although the incidence varies
according to the type of malignancy and treatment received.
Fatigue is the most commonly reported symptom in cancer
patients. During chemotherapy or radiotherapy fatigue is experi-
enced by the vast majority of patients (Smets et al, 1993) and long-
term follow-up has suggested that in some patient groups this may
persist for many years. However, most studies in cancer patients
have assessed fatigue by single items in a general symptom check-
list (Smets et al, 1993) and therefore do not provide an accurate
estimation of the degree of fatigue experienced by these patients.
Androgen deficiency is associated with increased fatigue,
sexual dysfunction and alterations in mood (Burris et al, 1992),
and testosterone replacement has been shown to improve these
abnormalities (Arver et al, 1996; Wang et al, 1996). We have
demonstrated that approximately one-third of men treated with
gonadotoxic chemotherapy for various haematological malignan-
cies have biochemical evidence of Leydig cell dysfunction
(Howell et al, 1999), and we have therefore hypothesized that mild
androgen deficiency may account for the increase in fatigue,
sexual dysfunction and alterations in mood observed in a propor-
tion of the patients treated with cytotoxic chemotherapy and radio-
therapy for cancer. In order to assess the contribution of mild
testosterone deficiency to alterations in these parameters we have
assessed energy, sexual function and mood in a group of men with
Leydig cell dysfunction following successful cancer treatment and
compared the results with a similar cohort who had entirely
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results to those obtained in healthy men, where such data are avail-
able, so that we can also assess the overall impact of the malig-
nancy and its treatment.
PATIENTS
We screened a total of 209 men who had been treated with either
MVPP (mustine, vinblastine, procarbazine and prednisolone),
Ch1VPP/EVA hybrid (chlorambucil, vinblastine, procarbazine,
prednisolone, etoposide, vincristine and doxorubicin) or high-dose
chemotherapy (either cyclophosphamide, BCNU and etoposide,
busulphan and cyclophosphamide, high-dose cyclophosphamide
or high-dose melphalan). All patients were in remission at the time
of analysis, and had completed chemotherapy at least 12 months
previously. None had any history of testicular disease or had
received radiotherapy to the testes. Leydig cell impairment was
defined arbitrarily by a raised luteinizing hormone (LH) level 
(³ 8 IU l–1) in the presence of a testosterone level in the lower half
of the normal range or frankly subnormal (< 20 mmol l–1) (Howell
et al, 1999). We identified a total of 67 men who satisfied these
criteria for impaired Leydig cell function, and of these, 36 men
completed the questionnaires (group 1). Of the remaining 142
patients, 95 had entirely normal hormone levels (testosterone 
> 10 nmol l–1 and LH < 8 IU l–1), and of these, 61 men were
approached to complete the questionnaires. These patients were
selected on the basis of hormone levels, and in addition an attempt
was made to match this group for age with the 36 patients with
Leydig cell impairment. Of the 61 men approached, 30 completed
the questionnaires (group 2). There was no significant difference
in diagnosis, treatment, or hormone levels between those subjects
who completed the questionnaires and those who did not, and the 
66 patients in the study are therefore representative of the cohort
as a whole. The diagnosis and treatment of these 66 patients is
shown in Table 1. In addition to chemotherapy, 39 men received
radiotherapy (XRT): 25 of the 36 patients and 15 of the controls.
The neck, chest and mantle areas were the areas irradiated in 
the majority of subjects, although seven received total body
irradiation before bone marrow transplantation (BMT) and five
received XRT to the abdomen or pelvis.
All 66 patients completed three questionnaires. Mood was
assessed using the hospital anxiety and depression scale (HADS).
This is a 14-item questionnaire which has been well validated as a
tool for identifying abnormal mood states. The HADS has been
used in studies of distress in cancer patients in general (Carroll et
al, 1993; Ibbotson et al, 1994; Aass et al, 1997) and specifically in
Hodgkin’s disease (Loge et al, 1997). It has been shown to
perform well in cancer patients free of disease (Ibbotson et al,
1994). The HADS contains two 7-item scales, one for depression
and one for anxiety, both with a score range of 0–21. A score of
eight or above suggests the possibility of clinical disease
(Zigmond and Snaith, 1983; Carroll et al, 1993; Aass et al, 1997),
whilst a score of ³ 11 is indicative of likely anxiety or depression
(Zigmond and Snaith, 1983). The total score has also been used to
determine the presence of abnormal mood states, with cut-offs of
13 and 19 being used previously in studies of cancer patients
(Razavi et al, 1990; Carroll et al, 1993).
Sexual function was assessed using a questionnaire adapted
from a sexual diary developed for trials of the male contraceptive
pill. It asked the subjects about their interest in sex, frequency and
enjoyment of intercourse and masturbation, and frequency of early
morning erections over the previous 7 days.
Fatigue was assessed using a questionnaire specifically
designed for cancer patients; the multidimensional fatigue inven-
tory (MFI) 20. This is a 20-item questionnaire which has been
validated in patients with malignant disease (Smets et al, 1996).
The MFI-20 assesses five different aspects of fatigue: general
fatigue, physical fatigue, reduced activity, reduced motivation and
mental fatigue, with a score of 4–20 for each section. Normal data
for the MFI-20 from a group of 139 healthy Dutch subjects have
previously been reported (Smets et al, 1998). Forty-four of these
individuals were males under the age of 60 years, and this cohort
was used for comparison with the cancer patients (normals).
Information regarding education level was also collected for all
the subjects as this has been found to correlate with the incidence
of anxiety and depression (Loge et al, 1997).
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Table 1 Diagnosis and chemotherapy regimens used for treatment of the patients and controls
Diagnosis Treatment
Group 1 Hodgkin’s disease 25 MVPP alone 12
Hybrid alone 6
MVPP + Hybrid 3
HDCTa 4
Non-Hodgkin’s lymphoma 4 HDCT + VAPEC-B 3
HDCT + CHOP 1
Multiple myeloma 4 HDCT 4
Acute myeloid leukaemia 2 HDCT 2
Acute lymphoblastic leukaemia 1 HDCT 1
Group 2 Hodgkin’s disease 22 MVPP alone 4
Hybrid alone 13
MVPP + Hybrid 2
HDCTa 3
Non-Hodgkin’s lymphoma 3 HDCT + VAPEC-B 3
Acute myeloid leukaemia 5 HDCT 5
MVPP – Mustine, vinblastine, procarbazine and prednisolone. Ch1VPP/EVA Hybrid –
chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and doxorubicin.
HDCT – High-dose chemotherapy. VAPEC-B – Vincristine, doxorubicin, prednisolone, etoposide,
cyclophosphamide and bleomycin. CHOP – cyclophosphamide, doxorubicin, vincristine and
prednisolone. aHDCT for relapse following treatment with Ch1VPP/EVA Hybrid, MVPP or both.Mann–Whitney U and Student’s t-tests were used to compare
non-parametric and parametric data between groups. The influ-
ence of independent parameters on quality of life measures was
assessed using multivariate regression analysis, whilst correlations
between outcome variables were expressed as Pearson’s or
Spearman’s correlation coefficients (r).
RESULTS
Mean age, level of education, mean number of cycles of chemo-
therapy, time since treatment and hormone levels in group 1, group
2 and normal men are displayed in Table 2. There were no signifi-
cant differences in age between any of the groups, and no signifi-
cant differences in number of cycles of chemotherapy, time since
treatment or level of education between group 1 and 2. Patients in
group 1 had significantly higher LH and follicle stimulating
hormone (FSH) levels and significantly lower testosterone levels
than group 2 patients.
There were no significant differences in mean anxiety or depres-
sion scores between patients in group 1 and group 2, and no signif-
icant difference in the proportion of subjects in each of the groups
who had scores above the two suggested cut-offs. Forty-one per
cent of the whole cohort had an anxiety score greater than seven,
with 15% having a score above 10, whilst only 12% and 2% had
depression scores above seven and 10 respectively. Anxiety and
depression scores were significantly correlated with each other 
(r = 0.54, P < 0.001), but not with any of the hormonal parameters.
Patients treated with XRT had a significantly higher mean depres-
sion score than those who were not (4.4 vs 2.9; P = 0.03).
The results concerning sexual function are illustrated in Table 4.
Eighty-seven per cent of group 2 were sexually active compared
with only 69% of group 1 (c2 test P = 0.1). In addition, group 1
patients engaged less in sexual activity than those in group 2
(mean of 1.8 times per week compared with 3.2 times per week; 
P = 0.02) and tended to have fewer early morning erections (mean
per week 1.8 vs 2.3; P = 0.4). No patients reported any problems
with ejaculation or enjoyment of intercourse.
Mean fatigue scores for the patients are displayed in Table 5
along with mean scores obtained from normal healthy men. There
were no significant differences in any of the fatigue subscales
between groups 1 and 2. Compared with normal men the patients
had significantly higher mean general fatigue, physical fatigue and
mental fatigue. When the 66 subjects were split according to treat-
ment with XRT it was apparent that compared with patients not
treated with XRT, those who received XRT had significantly
higher mean scores for general fatigue (13.4 vs 11.5; P < 0.05),
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Table 2 Age, number of cycles of chemotherapy, education level, time since treatment and hormonal
parameters in the patients and controls. Age, number of cycles and years since treatment are
expressed as medians (range), and hormonal variables are expressed as means (standard deviation)
Group 1 (n = 36) Group 2 (n = 30) Normals (n = 44)
Age (years) 42 (27–52) 38.5 (21–51) 40.3 (20–59)
No. of cycles 7.5 (3–11) 7.0 (6–11) –
Education level
Less than 16 years 1 3 2
Up to 16 years 25 14 8
Up to 18 years 6 8 24
Beyond 18 years 4 5 10
Years since treatment 8.0 (1–21) 8.0 (1–17) –
Testosterone (nmol l–1) 13.5 (3.5)a 20.2 (6.9) –
SHBG (nmol l–1) 30.6 (13.3) 31.4 (8.0) –
LH (IU l–1) 10.2 (2.4)a 5.4 (1.5) –
FSH (IU l–1) 23.8 (7.8)a 13.2 (5.9) –
Testosterone/SHBG 0.51 (0.21)b 0.66 (0.19) –
Testosterone/LH 1.4 (2.45) 4.1 (0.48)a –
aP < 0.0001; bP = 0.002.
Table 3 Mean HAD scores for patients and controls and number (%) with
an anxiety or depression score of ³ 8 and ³ 11, and number (%) with a total
score ³ 13 and ³ 19.
Group 1 Group 2 All
(n = 36) (n = 30) (n = 66)
Anxiety Mean score 7.4 6.5 7.0
³ 8 14 (39%) 13 (43%) 27 (41%)
³ 11 7 (19%) 3 (10%) 10 (15%)
Depression Mean score 4.1 3.7 3.9
³ 8 5 (14%) 3 (10%) 8 (12%)
³ 11 1 (3%) 0 1 (2%)
Total Mean score 11.6 10.2 11
³ 13 15 (42%) 11 (37%) 26 (39%)
³ 19 3 (8%) 1 (3%) 4 (6%)
Table 4 Sexual function in the patients and controls over the previous 7
days. Sexual activity refers to either intercourse or masturbation. Enjoyment
and sexual interest were scored by patients between 1 and 5 and results are
expressed as mean scores
Group 1 Group 2
(n = 36) (n = 30)
Sexual activity
Yes/No 25/11 (69%/31%) 26/4 (87%/13%)
Frequency (times/week) 1.8 3.2a
Ejaculatory problems 0 0
Enjoyment score 4.1 4.1
Early morning erections
Yes/No 25/11 (69%/31%) 20/10 (67%/33%)
Frequency (times/week) 1.8 2.3
Sexual interest 3.0 3.4
aP = 0.02.and a non-significantly trend towards higher scores for mental
fatigue (11.3 vs 9.2; P = 0.07).
Multiple linear regression analysis was performed to assess the
relative effects on quality of life of age, hormone levels, diagnosis,
chemotherapy regimen, treatment with XRT, number of cycles of
chemotherapy and time since treatment. This demonstrated no
effect of diagnosis, chemotherapy regimen, number of cycles of
chemotherapy or time since treatment on mood, sexual function or
fatigue. In addition, the effect of treatment with XRT on fatigue
scores and depression score did not reach statistical significance
once it had been corrected for the other variables. Testosterone
level significantly correlated with sexual activity (P < 0.01) and
sexual interest (P < 0.05), whilst age inversely correlated with
these two measures (P < 0.05). There were significant correlations
between mood, sexual function and fatigue which are illustrated in
Table 6.
DISCUSSION
We have assessed several aspects of quality of life in men
following treatment with cytotoxic chemotherapy, with or without
radiotherapy. We have attempted to ascertain the contribution of
mild Leydig cell dysfunction to alterations of sexual function,
energy levels and mood by comparing a group of men with raised
LH and low/normal testosterone levels with a group with normal
hormone levels. Where possible, we have also compared the
results with existing data from normal healthy men. Because of the
large number of comparisons performed, the significance of some
of the results must be interpreted with caution.
We found no difference in anxiety or depression score between
patients with Leydig cell dysfunction and those with normal
hormone levels. There is some evidence that overt hypogonadism
is associated with alterations in mood and that these are reversed
by androgen replacement (Wang et al, 1996). Our data suggest,
however, that the milder degrees of testosterone deficiency in our
cohort have no significant effect on mood. The rate of anxiety
using the two suggested thresholds (8 and 11) was higher than that
observed in normal healthy adults. Forty-one per cent and 15% of
the patients had anxiety scores greater than seven and ten
compared with 20% and 8% of a normal population studied by
Lisspers et al 1997). It is not surprising, however, that higher rates
of anxiety should be found in a group of men with a previous diag-
nosis of cancer, and results from other studies using the HADS
carried out in patients treated for cancer have shown similar rates
of anxiety (Moorey et al, 1991; Carroll et al, 1993; Loge et al,
1997).
The questionnaire regarding sexual function showed reduced
sexual activity in the patients with Leydig cell dysfunction
compared with those with normal hormone levels, and multi-
variate analysis demonstrated an effect of testosterone levels on
sexual interest and activity. Several studies have found high rates
of sexual dysfunction in treated cancer patients. Sexual problems
were reported by 24% of treated Hodgkin’s disease patients
studied by Kornblith et al (1992) and less interest in sexual activity
was reported by 20% of a similar group studied by Fobair et al
(1986). Rates of sexual dysfunction following BMT have been
described in between 20 and 50% of patients (Hjermstad and
Kassa, 1995; Marks et al, 1997). Testosterone is important for
determining sexual desire and erectile function and will therefore
impact on sexual activity. Overt hypogonadism is associated with
reduced sexual function which responds to androgen replacement
(Arver et al, 1996), but the effect of milder degrees of testosterone
deficiency have not been clearly defined. Whilst there are a
number of possible factors contributing to the reduction in sexual
function following cancer treatment (e.g. psychological stress
associated with a life-threatening disorder or an effect of
chemotherapy or XRT on penile blood flow or nerve supply), the
difference in sexual activity that we observed between the groups
suggests that mild Leydig cell insufficiency may be important.
We observed no difference in fatigue scores between patients in
groups 1 and 2, suggesting that mild hypogonadism is not an
important factor in determining energy levels in these patients.
Fatigue scores in our subjects were, however, significantly greater
than those observed in normal individuals. This is in contrast to
results using the MFI-20 in patients who received radiotherapy for
various malignancies, in whom no significant increase in any
dimension of fatigue was demonstrated (Smets et al, 1998). We
found significant correlations between mood and level of fatigue
and there was a significantly higher level of general fatigue in
those patients who received XRT. This suggests that treatment
with XRT is aetiologically important in the development of fatigue
in these patients and that mood may affect the perception of tired-
ness.
There are numerous studies which have reported high rates 
of fatigue during treatment of malignancies with XRT or
chemotherapy (Smets et al, 1993). There are few published data,
however, concerning the incidence of fatigue in long-term
survivors of cancer, and most of the studies have not used ques-
tionnaires specifically designed to measure energy levels. Fatigue
has been reported to occur commonly in survivors of Hodgkin’s
disease. Devlen et al (1987) reported loss of energy in 42% and
tiredness in 32% of 120 patients with Hodgkin’s disease and non-
Table 6 Relationship between scores for mood, sexual function and fatigue
Depression Anxiety
Correlation P-value Correlation P-value
coefficient coefficient
Sexual interest –0.38 = 0.001 NS
Sexual activity –0.33 = 0.007 NS
General fatigue 0.64 < 0.001 0.47 < 0.001
Physical fatigue 0.57 < 0.001 NS
Reduced activity 0.54 < 0.001 0.31 = 0.01
Reduced motivation 0.53 < 0.001 0.52 < 0.001
Mental fatigue 0.46 < 0.001 0.52 < 0.001
NS = non-significant.
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Table 5 Mean fatigue scores for patients, controls and normal healthy men
Group 1 Group 2 All subjects Normal men
(n = 36) (n = 30) (n = 66) (n = 44)
General fatigue 12.8b 12.6b 12.7c 9.6
Physical fatigue 12.5d 11.5b 12.0d 8.5
Reduced activity 9.3 10.0 9.6 8.7
Reduced motivation 9.0 9.3 9.1a 8.3
Mental fatigue 10.6a 10.8a 10.7b 8.2
aP < 0.05, bP < 0.005, cP < 0.001, d P < 0.0001 compared with normal men.Hodgkin’s lymphoma 1 year after the diagnosis, despite the fact
that the majority of patients had finished treatment and were in
remission. A cross-sectional survey of long-term survivors of
Hodgkin’s disease a median of 9 years after treatment indicated
that energy levels had not returned to patients’ satisfaction in 37%
(Fobair et al, 1986). In addition, in keeping with our results, they
found an association between depression and energy levels in
these patients (Fobair et al, 1986).
The mechanism by which cancer therapy causes fatigue in long-
term survivors is not understood. Several possibilities exist to
explain a reduction in energy during treatment, such as poor nutri-
tion, the accumulation of toxic metabolites, anaemia or the side-
effects of certain drugs. However, none of these adequately
explain the persistence of fatigue long after the cessation of treat-
ment. Abnormal mood states are more common in patients
following cancer treatment and can be associated with decreased
energy levels. We have been able to confirm that the level of
depression correlates with fatigue in our cohort, although the lack
of any significant increase in depression score compared with
normal men suggests that this is not the only cause. In addition,
our data confirm that treatment with radiotherapy is associated
with increased fatigue in survivors of malignancy. We had postu-
lated that mild Leydig cell dysfunction may be one mechanism by
which cancer treatment may result in long-term fatigue. However,
the lack of any significant difference in fatigue score between the
patient groups in our study argues against an effect of mild hypo-
gonadism.
In summary, we have shown higher levels of fatigue and anxiety
in a group of patients who have been successfully treated with
cytotoxic chemotherapy ± XRT for various malignancies
compared with normal healthy men. Our data indicate that mild
Leydig cell dysfunction is not the cause for these abnormalities,
but may have an effect on sexual function. The results do not
provide a convincing argument for mandatory androgen replace-
ment therapy in the majority of these patients, although it may be
beneficial in a minority. To establish whether androgen therapy is
ever of any benefit in these patients a randomized placebo-
controlled trial will be necessary.
REFERENCES
Aass N, Fossa SD, Dahl AA and Moe TJ (1997) Prevalence of anxiety and
depression in cancer patients seen at the Norwegian Radium Hospital. Eur J
Cancer 33: 1597–1604
Ahles TA, Tope DM, Furstenberg C, Hann D and Mills L (1996) Psychologic and
neuropsychologic impact of autologous bone marrow transplantation. J Clin
Oncol 14: 1457–1462
Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW and Mazer NA (1996)
Improvement of sexual function in testosterone deficient men treated for 1 year
with a permeation enhanced testosterone transdermal system. J Urol 155:
1604–1608
Berglund G, Bolund C, Fornander T, Rutqvist LE and Sjoden PO (1991) Late effects
of adjuvant chemotherapy and postoperative radiotherapy on quality of life
among breast cancer patients. Eur J Cancer 27: 1075–1081
Bjordal K, Kaasa S and Mastekaasa A (1994) Quality of life in patients treated for
head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J
Radiat Oncol Biol Phys 28: 847–856
Bloom JR, Fobair P, Gritz E, Wellisch D, Spiegel D, Varghese A and Hoppe R
(1993) Psychosocial outcomes of cancer: a comparative analysis of Hodgkin’s
disease and testicular cancer. J Clin Oncol 11: 979–988
Burris AS, Banks SM, Carter CS, Davidson JM and Sherins RJ (1992) A long-term,
prospective study of the physiologic and behavioral effects of hormone
replacement in untreated hypogonadal men. J Androl 13: 297–304
Carroll BT, Kathol RG, Noyes R, Jr, Wald, TG and Clamon GH (1993) Screening for
depression and anxiety in cancer patients using the Hospital Anxiety and
Depression Scale. Gen Hosp Psychiatry 15: 69–74
Devlen J, Maguire P, Phillips P and Crowther D (1987) Psychological problems
associated with diagnosis and treatment of lymphomas. II: Prospective study.
Br Med J Clin Res Ed 295: 955–957
Fobair P, Hoppe RT, Bloom J, Cox R, Varghese A and Spiegel D (1986)
Psychosocial problems among survivors of Hodgkin’s disease. J Clin Oncol 4:
805–814
Greenberg DB, Kornblith AB, Herndon JE, Zuckerman E, Schiffer CA, Weiss RB,
Mayer RJ, Wolchok SM and Holland JC (1997) Quality of life for adult
leukemia survivors treated on clinical trials of Cancer and Leukemia Group B
during the period 1971–1988: predictors for later psychologic distress. Cancer
80: 1936–1944
Hjermstad MJ and Kaasa S (1995) Quality of life in adult cancer patients treated
with bone marrow transplantation – a review of the literature. Eur J Cancer,
31a: 163–173
Howell SJ, Radford JA and Shalet SM (1999) Testicular function following
cytotoxic chemotherapy – evidence of Leydig cell insufficiency. Clin Oncol (In
press)
Ibbotson T, Maguire P, Selby P, Priestman T and Wallace L (1994) Screening for
anxiety and depression in cancer patients: the effects of disease and treatment.
Eur J Cancer 30a, 37–40
Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman E, Cherin E, Henderson
ES, Canellos GP, Kosty MP, Cooper MR, Weiss RB, Gottleib A and Holland
JC (1992) Comparison of psychological adaptation and sexual function of
survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP
alternating with ABVD, Cancer, 70, 2508–2516
Lisspers J, Nygren A, and Soderman E (1997) Hospital Anxiety and Depression
Scale (HAD): some psychometric data for a Swedish sample. Acta Psychiatry
Scand, 96, 281–286
Loge JH, Abrahamsen AF, Ekeberg O, Hannisdal E and Kaasa S (1997)
Psychological distress after cancer cure: a survey of 459 Hodgkin’s disease
survivors. Br J Cancer, 76, 791–796
Marks S, Friedman SH, Delli Carpini L, Nezu CM and Nezu AM (1997) A
prospective study of the effects of high-dose chemotherapy and bone marrow
transplantation on sexual function in the first year after transplant. Bone
Marrow Transplant, 19, 819–822
Moorey S, Greer S, Watson M, Gorman C, Rowden L, Tunmore R, Robertson B and
Bliss J (1991) The factor structure and factor stability of the hospital anxiety
and depression scale in patients with cancer [see comments]. Br J Psychiatry,
158, 255–259
Razavi D, Delvaux N, Farvaques C and Robaye E (1990) Screening for adjustment
disorders and major depressive disorders in cancer in-patients [see comments].
Br J Psychiatry, 156, 79–83
Smets EM, Garssen B, Schuster Uitterhoeve AL and de Haes JC (1993) Fatigue in
cancer patients. Br J Cancer, 68, 220–224
Smets EM, Garssen B, Cull A and de Haes, JC (1996) Application of the
multidimensional fatigue inventory (MFI–20) in cancer patients receiving
radiotherapy. Br J Cancer, 73, 241–245
Smets EM, Visser MR, Willems Groot AF, Barssen B, Schuster Uitterhoeve AL and
de Haes JC (1998) Fatigue and radiotherapy: (B) experience in patients 9
months following treatment. Br J Cancer, 78, 907–912
Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B,
Hull L, Callegari C and Swerdloff RS (1996) Testosterone replacement therapy
improves mood in hypogonadal men: -a clinical research canter study. J Clin
Endocrinol Metab, 81, 3578–3583
Zigmond AS and Snaith RP (1983) The hospital anxiety and depression scale. Acta
Psychiatry Scand, 67, 361–370
Quality of life and mild hypogonadism after cancer treatment 793
British Journal of Cancer (2000) 82(4), 789–793 © 2000 Cancer Research Campaign